1.49

6.79% 0.09

Prelude Therapeutics Inc (PRLD)

Overview News Price History Option Chain Financials Discussions Forecast

Prelude Therapeutics Inc stock is traded at $1.49, with a volume of 605.14K. It is up +6.79% in the last 24 hours and down -7.72% over the past month. Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Previous Close:

$1.40

Open:

$1.42

24h Volume:

605.14K

Relative Volume:

0.48

Market Cap:

$93.67M

Revenue:

Net Income/Loss:

$-131.52M

P/E Ratio:

-0.8371

EPS:

-1.78

Net Cash Flow:

$-107.56M

1W Performance:

-11.01%

1M Performance:

-7.72%

6M Performance:

+68.70%

1Y Performance:

+55.05%

1-Day Range:

$1.32

$1.5028

1-Week Range:

$1.32

$1.70

52-Week Range:

$0.6101

$4.22

Prelude Therapeutics Inc Stock (PRLD) Company Profile

Name

Prelude Therapeutics Inc

Sector

Healthcare (1138)

Industry

Biotechnology (635)

Phone

(302) 467-1280

Address

175 INNOVATION BOULEVARD, WILMINGTON

Employee

131

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

PRLD's Discussions on Twitter

Compare PRLD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PRLD Prelude Therapeutics Inc	1.49	88.01M	0	-131.52M	-107.56M	-1.78
VRTX Vertex Pharmaceuticals Inc	429.04	107.58B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	782.48	80.03B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	430.84	57.37B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	907.72	55.83B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	207.36	44.13B	447.02M	-1.18B	-906.14M	-6.1812

Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-19-24	Upgrade	H.C. Wainwright	Neutral → Buy
Jun-20-24	Downgrade	Barclays	Equal Weight → Underweight
Mar-13-24	Initiated	JMP Securities	Mkt Outperform
Feb-20-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-21-22	Downgrade	BofA Securities	Neutral → Underperform
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jul-29-22	Initiated	Jefferies	Buy
Mar-15-22	Downgrade	BofA Securities	Buy → Neutral
Feb-28-22	Downgrade	Barclays	Overweight → Equal Weight
Oct-08-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jul-27-21	Upgrade	BofA Securities	Neutral → Buy
Apr-26-21	Initiated	H.C. Wainwright	Buy
Mar-09-21	Initiated	Barclays	Overweight
Nov-20-20	Downgrade	BofA Securities	Buy → Neutral
Oct-20-20	Initiated	BofA Securities	Buy
Oct-20-20	Initiated	Goldman	Neutral
Oct-20-20	Initiated	Morgan Stanley	Equal-Weight

View All

Prelude Therapeutics Inc Stock (PRLD) Latest News

07:08 AM

This trade activity should not be overlooked: Prelude Therapeutics Inc (PRLD) - Setenews

07:08 AM

Nov 21, 2025

Prelude Therapeutics Experiences Revision in Its Stock Evaluation Amid Mixed Financial Trends - Markets Mojo

Nov 21, 2025

Nov 20, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics IncorporatedPRLD - PR Newswire

Nov 20, 2025

Nov 19, 2025

Will Prelude Therapeutics Incorporated stock outperform Dow Jones indexJuly 2025 Sentiment & Smart Money Movement Alerts - newser.com

Nov 19, 2025

Is Prelude Therapeutics Incorporated stock supported by innovation pipeline2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com

Nov 19, 2025

PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation ... - Bakersfield.com

Nov 19, 2025

PRLD Investors Have Opportunity to Join Prelude - GlobeNewswire

Nov 19, 2025

What to do if you’re stuck in Prelude Therapeutics IncorporatedPortfolio Update Summary & Smart Investment Allocation Insights - newser.com

Nov 19, 2025

Is Prelude Therapeutics Incorporated stock ready for a breakoutJuly 2025 Sector Moves & Weekly Market Pulse Updates - newser.com

Nov 19, 2025

What sentiment indicators say about Prelude Therapeutics Incorporated stock2025 Valuation Update & Safe Capital Growth Stock Tips - newser.com

Nov 19, 2025

Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 - MyChesCo

Nov 19, 2025

Nov 18, 2025

Order flow analysis tools used on Prelude Therapeutics IncorporatedJuly 2025 Sector Moves & Daily Volume Surge Signals - newser.com

Nov 18, 2025

Nov 17, 2025

Can Prelude Therapeutics Incorporated stock hit analyst price targets2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com

Nov 17, 2025

Real time alert setup for Prelude Therapeutics Incorporated performanceProduct Launch & Safe Entry Trade Signal Reports - newser.com

Nov 17, 2025

Is Prelude Therapeutics Incorporated stock supported by strong fundamentalsJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com

Nov 17, 2025

Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MyChesCo

Nov 17, 2025

Using flow based indicators on Prelude Therapeutics Incorporated2025 Market Sentiment & Fast Moving Trade Plans - newser.com

Nov 17, 2025

Taking on analysts’ expectations and winning: Prelude Therapeutics Inc (PRLD) - Setenews

Nov 17, 2025

Prelude Therapeutics’ Earnings Call Highlights Strategic Moves and Challenges - MSN

Nov 17, 2025

Nov 16, 2025

Published on: 2025-11-16 22:10:23 - newser.com

Nov 16, 2025

What institutional flow reveals about Prelude Therapeutics IncorporatedJuly 2025 Earnings & Safe Capital Growth Tips - newser.com

Nov 16, 2025

Is Prelude Therapeutics Incorporated stock a defensive play in 2025Weekly Risk Summary & Daily Oversold Bounce Ideas - newser.com

Nov 16, 2025

How to build a custom watchlist for Prelude Therapeutics IncorporatedJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com

Nov 16, 2025

Pattern recognition hints at Prelude Therapeutics Incorporated upsideSwing Trade & Advanced Technical Analysis Signals - newser.com

Nov 16, 2025

Nov 15, 2025

How moving averages guide Prelude Therapeutics Incorporated tradingBuy Signal & Weekly Breakout Watchlists - newser.com

Nov 15, 2025

Can Prelude Therapeutics Incorporated stock sustain free cash flow growthJuly 2025 Price Swings & Community Trade Idea Sharing Platform - newser.com

Nov 15, 2025

Nov 14, 2025

Volume spikes in Prelude Therapeutics Incorporated stock – what they meanMarket Performance Report & Daily Stock Momentum Reports - newser.com

Nov 14, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 14, 2025

Will Prelude Therapeutics Incorporated stock deliver shareholder valueTrade Exit Summary & AI Forecast for Swing Trade Picks - newser.com

Nov 14, 2025

Prelude Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada

Nov 14, 2025

Published on: 2025-11-14 02:04:28 - newser.com

Nov 14, 2025

Nov 13, 2025

Prelude Therapeutics Advances Pipeline and Strengthens Financials - TipRanks

Nov 13, 2025

Nov 12, 2025

Transcript : Prelude Therapeutics Incorporated, Q3 2025 Earnings Call, Nov 12, 2025 - MarketScreener

Nov 12, 2025

Can Prelude Therapeutics Incorporated stock maintain operating margins2025 Key Lessons & Expert Approved Momentum Trade Ideas - newser.com

Nov 12, 2025